Introduction {#Sec1}
============

Myocardial infarction (MI) remains a leading cause of death and disability worldwide. In the United States alone, approximately 1 million cases of MI occur annually (Roger et al. [@CR71]). The implementation of cardiovascular prevention strategies continues to reduce the incidence of MI. Concurrently, however, evolution of pharmacological approaches and coronary reperfusion interventions has led to an increased post-MI survival rate, which in turn has raised MI disease morbidity. Previous estimates indicate that approximately 90--95% of patients survive their first MI (Rosamond et al. [@CR72]), contributing to a current "epidemic" of heart failure and imposing an enormous health burden on individuals and the community.

After MI, local cardiac compensatory mechanisms are activated giving rise to a vicious cycle of cardiac metabolic insufficiency, leading to heart failure and potentially sudden death (Orn et al. [@CR64]). Timely reperfusion together with optimal drug and device-based interventions has improved MI management by reducing the initial burden of injury and slowing progression of resultant adverse remodeling (White et al. [@CR98]). Nevertheless, no current therapy is able to reverse the inexorable decline in cardiac function. Therefore, new strategies investigating cardiac regeneration have demanded considerable interest. These involve either 1) the implantation of stem cells or their derivatives directly into the heart or 2) the activation of endogenous cardiac repair mechanisms in order to replace damaged cardiomyocytes and promote vascular reconstruction (Laflamme and Murry [@CR38]).

This review provides physicians with a concise overview of the major types of stem cells, both from cardiac or extra-cardiac origins, being investigated for post-MI treatment. For further detail and information on endogenous cardiac regeneration, the interested reader is directed to the following detailed reviews (Laflamme and Murry [@CR38]; Choi and Poss [@CR13]; Rasmussen et al. [@CR69]).

Extra-cardiac stem cells {#Sec2}
========================

Skeletal myoblasts {#Sec3}
------------------

Skeletal myoblasts (SKM) are the progenitor cells of skeletal muscle. Initial observations that SKMs could be harvested from an autologous origin, easily expanded ex vivo and undergo spontaneous differentiation into contractile muscle sparked interest in SKMs for cardiac myoplasty (Taylor et al. [@CR86]). Early uncontrolled clinical studies reported that SKMs could engraft in the injured heart with remarkable efficiency and enable significant improvement in cardiac function (Menasche et al. [@CR52]). These findings were not reproduced in a subsequent prospective randomized placebo-controlled trial (Menasche et al. [@CR53]), where 97 participants with severe left ventricular (LV) dysfunction underwent transepicardial autologous SKM injection at the time of coronary artery bypass grafting. Six months following the procedure, no improvement in LV function was found when compared to placebo. Importantly, a high prevalence of ventricular tachyarrhythmias was observed leading to premature discontinuation of the trial. Similar results were observed in the SEISMIC trial which used transendocardial injection of autologous SKMs (Veltman et al. [@CR93]). A follow-up study conducted four years later reported no significant change in LV function compared to the placebo group.

The general consensus amongst clinicians now is that SKMs do not electrically couple to host cardiomyocytes (Leobon et al. [@CR41]). Notably, it is now understood that the gap-junction protein, connexin 43, can augment intracellular coupling of cardiomyocytes and confers a protective effect against ventricular tachyarrhythmias following cell transplantation (Roell et al. [@CR70]).

Bone marrow mononuclear cells {#Sec4}
-----------------------------

The major stem cell type in the bone marrow (BM) is the hematopoietic stem cell (HSC). HSCs comprise less than 0.1% of unfractionated bone marrow mononuclear cell (BMMNC) samples (Challen et al. [@CR12]). Although the vast majority of BMMNCs are not stem cells, they are still considered a significant source of hematopoietic progenitors which may be useful for cardiac repair. In 2001, a landmark murine study administered BM- derived HSCs by direct intramyocardial injection into infarcted murine hearts (Orlic et al. [@CR63]). The transplanted cells reportedly underwent transdifferentiation directly into cardiomyocytes and supporting vasculature leading to improved LV function. These results were wholeheartedly embraced by clinicians and a wave of clinical trials using BMMNCs for cardiac regeneration ensued. The first of these reports using BM cardiac cell therapy appeared only months after this initial murine publication (Strauer et al. [@CR81]) which proved to be highly controversial. Several high profile groups have been unable to replicate its findings (Murry et al. [@CR59]; Balsam et al. [@CR5]). It is now generally believed that transdifferentiation of HSCs to cardiomyocytes does not occur to any meaningful degree. Importantly however, cardiac cell therapy with BMMNCs may rely on other mechanisms to achieve favorable cardiac repair after MI. This may include secretion of growth factors and other proteins capable of promoting angiogenesis (Ruger et al. [@CR74]) and endogenous cardiac stem cell or cardiomyocyte proliferation (Laflamme and Murry [@CR38]).

Clinical trials using BMMNCs for cardiac repair have now been the subject of several meta-analyses (Abdel-Latif et al. [@CR1]; Martin-Rendon et al. [@CR50]; Clifford et al. [@CR19]). Together, close to 2000 subjects have received BMMNCs as cell therapy for cardiac dysfunction (predominantly for ischemic cardiomyopathy). The pooled results suggest that this treatment appears safe but clinical improvements are modest. In fact, the very recent phase 2 FOCUS-CCTRN trial reported no significant improvement in LV end-systolic volume, further undermining the efficacy of BMMNCs (Perin et al. [@CR66]). Notably, most of the earlier trials used endpoints based on LV functional imaging or subjective symptom based questionnaires. No study has definitively examined hard clinical endpoints such as mortality. To this end, a large randomized multi-center European clinical trial investigating intracoronary delivery of BMMNCs after MI has commenced enrolment with its primary endpoint being all-cause mortality (NCT01569178) (Table [1](#Tab1){ref-type="table"}). If results are positive, this may lead to increased uptake of this novel treatment by clinical cardiologists.Table 1**Recent and ongoing clinical trials involving extra-cardiac stem cells in patients with ischemic cardiomyopathy**Trial name/InvestigatorStudy identifierComparatorsEndpointPatientsDelivery routeType classification**SKMs** MARVELNCT00526253Low dose vs high dose vs placeboSafety + QOL170IntramyocardialSafety + efficacy, Phase 1/2**BMCs** REPAIR-AMI\*NCT00279175BMC vs placeboLVEF204IntracoronaryEfficacy, Phase 3 REGEN-IHDNCT00747708Intracoronary BMC + G-CSF vs intramyocardial BMC + G-CSF vs G-CSF vs placeboLVEF148Intracoronary/IntramyocardialSafety + efficacy, Phase 2/3 BAMINCT01569178BMC vs no interventionAll-cause mortality3000IntramyocardialSafety + efficacy, Phase 3 REPEATNCT01693042Single vs repeated (2 times) BMC infusionsMortality + morbidity676IntracoronarySafety + efficacy, Phase 2/3 FOCUS\*NCT00824005BMMNC vs placeboLVESV92IntramyocardialSafety + efficacy, Phase 2 ASSURANCENCT00869024BMMNCs infusionMortality + morbidity24IntramyocardialSafety, Phase 1/2 REVITALIZENCT00874354BMMNCs infusionLVEF30IntracoronarySafety + efficacy, Phase 1**EPCs/CD133+ Cells** PERFECT\*NCT00950274CD133+ vs placeboLVEF142IntramyocardialEfficacy, Phase 3 Cardio133\*NCT00462774CD133+ vs placeboLVEF60IntramyocardialEfficacy, Phase 2/3 IMPACT-CABGNCT01033617CD133+ vs placeboSAE20IntramyocardialSafety + efficacy, Phase 2 AlsterMACSNCT01337011Intracoronary vs intramyocardial CD133+ infusionsLVEF64Intracoronary/IntramyocardialEfficacy, Phase 1/2 SELECT-AMINCT00529932CD133+ vs placeboLV wall thickness60IntracoronarySafety + efficacy**EPCs/CD133+ Cells vs BMCs** Baharvand et al.NCT01167751BMMNC vs CD133+ vs placebo infusionsLVEF105IntracoronarySafety + efficacy, Phase 3 Ghassemi et al.NCT01187654BMMNC vs CD133+ vs placebo infusionsLVEF80IntracoronarySafety + efficacy, Phase 2/3**MSCs** Adipose Tissue MSCs  ATHENANCT01556022MSCs vs placeboSAE + LVEF45IntramyocardialSafety + efficacy, Phase 2  ADVANCENCT01216995MSCs vs placeboSAE + Infarct size216IntracoronarySafety + efficacy, Phase 2  Parcero et al.NCT01502514MSCs infusionQOL10IntramyocardialSafety + efficacy, Phase 1/2 Umbilical Cord MSCs  Yan et al.NCT01946048MSCs vs placeboLVEF10IntramyocardialSafety + efficacy, Phase 1 Bone Marrow MSCs  ESTIMATIONNCT01394432MSCs vs placeboLVESV50IntramyocardialEfficacy, Phase 3  SEED-MSCNCT01392105MSCs vs no interventionLVEF80IntracoronarySafety + efficacy, Phase 2/3  Anastasiadis et al.NCT01753440Allogeneic MSCsLVEF30IntramyocardialSafety + efficacy, Phase 2/3  Anastasiadis et al.NCT01759212Allogeneic MSCsLVF10IntramyocardialSafety + efficacy, Phase 2/3  Perin et al.NCT0055582825 vs 75 vs 150 million allogeneic MSCs vs placeboSafety + LVF25IntramyocardialSafety + efficacy, Phase 1/2  PROMETHEUS\*NCT00587990Low vs high dose MSCs vs placeboSAE45IntramyocardialSafety + efficacy, Phase 1/2  MESAMINCT01076920MSCs infusionSafety + LVF10IntramyocardialSafety, Phase 1/2  MSC-HFNCT00644410MSCs vs placeboLVF60IntramyocardialSafety + efficacy, Phase 1/2 Allogeneic vs Autologous MSCs  POSEIDON-Pilot\*NCT01087996Auto-MSCs (20, 100 or 200 million) vs Allo-MSCs (20, 100 or 200 million)SAE + LVF30IntramyocardialSafety + efficacy, Phase 1/2 BMCs vs MSCs  TAC-HFT\*NCT00768066MSCs (100 or 200 million) vs BMCs (100 or 200 million) vs placeboSAE + LVF67IntramyocardialSafety + efficacy, Phase 1/2All trials use autologous infusions unless otherwise stated. BMC-Bone Marrow Stem Cell, BMMNC-Bone Marrow Mononuclear Cell, EPC-Endothelial Progenitor Cell, G-CSF-Granulocyte-Colony Stimulating Factor, LVEF-Left Ventricular Ejection Fraction, LVESV-Left Ventricular End Systolic Volume, LVF-Left Ventricular Function, MSC-Mesenchymal Stem Cell, QOL-Quality of Life, SAE-Serious Adverse Events, SKM-Skeletal Myoblast.\*Denotes trials with published results (including preliminary results).

Mesenchymal stem cells {#Sec5}
----------------------

In addition to HSCs, mesenchymal stem cells (MSCs) represent another group of stem cells found in the BM, as well as other tissues such as adipose tissue and cord blood. MSCs (also known as mesenchymal stromal cells or colony-forming unit fibroblasts) were first isolated over 40 years ago (Friedenstein et al. [@CR28]) and have been shown to directly transdifferentiate into cardiomyocytes in the presence of the demethylating agent 5-azacytidine (5-AZA) (Wakitani et al. [@CR95]) or when co-cultured with other cardiomyocytes (Rangappa et al. [@CR68]; Li et al. [@CR43]). Furthermore, MSCs possess several inherent features which facilitate their use in a clinical setting. In addition to being easily harvested and cultured ex vivo, MSCs are believed to be able to modulate the host immune system via lymphocyte regulation (Di Nicola et al. [@CR24]) and the suppression of inflammatory cytokine release from cells of the innate immune system (Aggarwal and Pittenger [@CR2]). These characteristics render MSCs a promising allogeneic cell source for treatment of infarcted hearts.

As with BMMNCs however, controversy surrounds their cardiomyogenic potential. In a study by Rose et al., BM-derived MSCs (BM-MSCs) did not transdifferentiate into functional cardiomyocytes in vitro (Rose et al. [@CR73]) but were able to express cardiomyocyte specific proteins. Regardless, MSCs remain the subject of considerable interest for cardiac repair strategies. They rapidly progressed through the pre-clinical arena, where small and large animal studies suggested potential to improve cardiac function after induced MI (Shake et al. [@CR77]; Schuleri et al. [@CR75]). Eventually clinical trials ensued. The first of these was a randomized, double blinded, placebo controlled phase 1 dose escalation study using intravenous allogeneic BM-MSC infusions after MI (Hare et al. [@CR30]). Here, MSC treatment appeared safe after twelve months of follow up. Unexpectedly, when addressing the arrhythmogenic potential of MSC transfusions, ambulatory electrocardiogram monitoring showed that arrhythmic risk had decreased. The investigators of this trial reported an improvement in the global symptom score at 6 months and a significant improvement in LV function at 3 but not 6 months. The latter finding was attributed to a "catch-up" phenomenon in ventricular function of placebo treated patients. Interestingly, similar "catch-up" has been reported in BMMNC therapy trials (Meyer et al. [@CR55]).

Recent trials also appear to support MSC derived improvements on cardiac dysfunction Table [1](#Tab1){ref-type="table"}. The phase 1/2 randomized POSEIDON trial investigated autologous compared to allogeneic MSCs in patients undergoing coronary artery bypass grafting for ischemic cardiomyopathy. Initial published results documented safety and overall efficacy (Hare et al. [@CR31]). Interestingly, further analysis of imaging data found that the functional effects of MSCs appeared preferentially at local sites of MSC injection whilst scar reduction was seen more globally (Suncion et al. [@CR82]). Similar effects of MSCs on scar were seen by Williams et al. who used percutaneous transendocardial injections (Williams et al. [@CR99]). The Transendocardial Autologous Cells in Ischemic Heart Failure Trial (TAC-HFT) also used percutaneous intramycoardial injections to compare efficacy of MSCs to BMMNCs (Heldman et al. [@CR32]). MSCs, but not BMMNCs, reduced infarct size and improved regional myocardial function. The Prospective Randomized Study of MSC Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) study used magnetic resonance imaging to investigate mechanisms by which MSCs may improve LV function (albeit in a very limited sample population of six patients) (Karantalis et al. [@CR36]). Myocardial segments injected with MSCs showed not only a reduction in scar size with corresponding increased contractile improvement, but also increased perfusion despite the lack of coronary artery bypass to these segments.

A different and novel approach was used in the recent C-CURE trial. Here the therapeutic effect of BM-MSCs exposed to a cytokine cocktail designed to induce partial cardiogenic differentiation was investigated (resulting cells were named cardiopoietic stem cells) (Bartunek et al. [@CR6]). The autologous cardiopoietic stem cells were delivered via transendocardial injection into the LV myocardium of patients suffering from an ischemic cardiomyopathy. Results showed that this strategy was feasible and appeared safe. Furthermore, LV function was significantly improved in the cardiopoietic stem cell therapy group compared to placebo (Bartunek et al. [@CR6]).

It is important to note that the mechanisms underpinning effects of MSC cardiac therapy are not yet completely understood. Inconsistent pre-clinical results demonstrating MSC differentiation into cardiomyocytes may be attributed to varied methods of MSC isolation and propagation. Significant MSC to cardiomyocyte transdifferentiation in the clinical trials discussed above seems unlikely since MSCs engraft poorly in cardiac tissue. Theories have now shifted to support a more indirect mechanism involving paracrine mediators that in turn contribute to angiogenesis or new host cardiomyocyte formation (either from resident cardiac stem cells or division of existing cardiomyocytes) (Williams et al. [@CR99], [@CR100]; Li et al. [@CR44]) (Figure [1](#Fig1){ref-type="fig"}).Figure 1**Schematic representation of the potential sequence of events involved in successful regenerative stem cell treatment of cardiac tissue in an infarcted heart.** BMMNC ‒ Bone Marrow Mononuclear Cell, CSC ‒ Cardiac Stem Cell, EPC ‒ Endothelial Progenitor Cell, ESC ‒ Embryonic Stem Cell, ICM ‒ Inner Cell Mass, iPSC ‒ Induced Pluripotent Stem Cell, MSC ‒ Mesenchymal Stem Cell, SKM ‒ Skeletal Myoblast.

Regarding origins, MSCs have reportedly been isolated from virtually all post-natal organs (da Silva Meirelles et al. [@CR20]), including the heart (Chong et al. [@CR15], [@CR16]). In particular, adipose tissue derived MSCs (AD-MSCs) have become the subject of recent research efforts. In preclinical rodent and porcine studies, these MSCs were shown to induce angiogenesis and significantly improve LV function (Valina et al. [@CR90]; Cai et al. [@CR11]). As a result, several clinical trials using AD-MSCs are currently being conducted (Table [1](#Tab1){ref-type="table"}).

Endothelial progenitor cells {#Sec6}
----------------------------

Early reports of another stem/progenitor cell population surfaced in 1997, when Asahara et al. described a population of BM-derived cells expressing CD34 (HSC marker) (Asahara et al. [@CR4]). Notably, CD34 is also expressed in a subset of endothelial cells. These cells were distinct from other BM-derived stem cell populations and were named endothelial progenitor cells (EPCs) due to their ability to differentiate ex vivo towards an endothelial cell lineage. Although expressing the cell surface proteins VEGFR2 and CD133 (Asahara et al. [@CR4]; Yin et al. [@CR101]), these markers are ubiquitously expressed, and hence EPCs lack a definitive marker for prospective identification and require in vitro assays for isolation and propagation.

The cardiac repair ability of EPCs lies in their potential to promote neovascularization, possibly by both direct (by differentiation into endothelial cells) and indirect (mediated by angiogenic growth factors) mechanisms. They are implicated in wound healing throughout the body. For this reason, these cells continue to be studied and may contribute clinically to cardiac repair post-MI as well as to angiogenesis in patients with refractory angina (Friis et al. [@CR29]). This is the focus of a currently recruiting phase 3 clinical trial called Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina (RENEW) (NCT01508910).

Pluripotent stem cells (embryonic stem cells/induced pluripotent stem cells) {#Sec7}
----------------------------------------------------------------------------

Embryonic stem cells (ESCs) extracted from the inner cell mass of a blastocyst (early-stage embryo) are able to give rise to cells of any of the 3 germ layers (Eckfeldt et al. [@CR25]). In the correct culture conditions, ESCs can differentiate into many different cells from varied organs. These cells thus possess formidable therapeutic potential and have been extensively studied. Three major concerns, however, have slowed their clinical translation. Firstly, undifferentiated pluripotent stem cells harbor great tumorigenic potential. Inadvertent transplantation of these undifferentiated cells poses significant risks to the receiving host. Secondly, ESCs will necessarily be used as an allogeneic product which is likely to induce host immune rejection following transplantation. Finally, ethical concerns held by some groups have created political hurdles in several countries. To some degree, the limitations above have been addressed and clinical trials using ESC-derived therapy have now become a reality (Schwartz et al. [@CR76]) (also see the ongoing 'Safety Study of GRNOPC1 in Spinal Cord Injury' trial, NCT01217008). With regards to cardiac therapy, several pre-clinical studies have demonstrated the ability of mouse (Min et al. [@CR56]) and human (Laflamme et al. [@CR39]; Fernandes et al. [@CR27]; Pearl et al. [@CR65]; Chong et al. [@CR17]) ESC-derived cardiomyocytes to engraft and repair the infarcted heart.

In 2006, a group led by Shinya Yamanaka reported the possibility of reprogramming differentiated somatic cells into a pluripotent state similar to ESCs (Takahashi and Yamanaka [@CR83]). These were named induced pluripotent stem cells (iPSCs) and the initial murine studies were replicated with human cells (Takahashi et al. [@CR84]). This method was embraced by scientists as a means to overcome the ethical dilemmas associated with ESC use. Furthermore, iPSCs could provide a theoretical means for a myriad of cell types to be made from a recipient's own somatic cells. The resultant cell therapy products would be syngenic (genetically identical) and theoretically would circumvent the host's immune system. Nevertheless, T-cell mediated immune rejection was evident in murine studies despite the use of syngenic iPSCs (Zhao et al. [@CR103]). In summary, pluripotent stem cells bare undeniable potential for large scale cardiac regeneration, but additional concerns must be addressed systematically to utilize their vast therapeutic abilities. The interested reader is directed to the following review covering recent translational efforts in this area (Chong and Murry [@CR14]).

Endogenous cardiac stem cells {#Sec8}
=============================

The notion of the heart being a terminally differentiated organ was first challenged almost a decade ago. Here, investigators reported the presence of possible endogenous cardiac stem cells (CSCs) in the human adult heart (Nadal-Ginard et al. [@CR60]). In human sex-mismatched cardiac transplants, female hearts transplanted into male hosts had a significant number of chromosome Y positive cardiomyocytes and coronary vessels expressing the stem cell markers c-kit, mdr1 or Sca-1 (Quaini et al. [@CR67]), suggesting that the adult heart may not be quiescent as previously thought. Since then, several cardiac stem cell populations have been isolated from various species, including humans. These populations possess the cardinal characteristics of stem cells, namely long term self-renewal, clonogenicity and multipotency, hence their regenerative potential holds great promise for cardiac therapeutics. In addition, it is expected that the restrictions in cardiomyocyte differentiation of extra-cardiac adult stem cells arises from epigenetic phenotypic restriction imposed on cells not of cardiac origin. To this end, it is likely that CSCs have greater potential for differentiation to cardiac cells, including cardiomyocytes. Here we review the major cell populations thought to be endogenous cardiac stem cells.

Isl-1+ cardiac stem cells {#Sec9}
-------------------------

Progenitor cells of the first and second heart fields in the developing heart depend on cardiac-specific transcription factors for their differentiation. Islet-1 (Isl-1) is a marker of cardiac progenitors arising from the second heart field (Klaus et al. [@CR37]). Substantial work using murine models of cardiogenesis have reported the progenitor phenotype of this population (Laugwitz et al. [@CR40]; Moretti et al. [@CR57]). Furthermore, in a report by Bu et al., transgenic and gene-targeting approaches in human embryonic stem cell lines demonstrated that purified Isl-1+ CSCs are pluripotent, revealing their ability to form cardiomyocytes, endothelial cells, vascular smooth muscle and cardiac conduction tissue (Bu et al. [@CR10]). This population of cells was proven to be distinct from other CSC populations (c-kit, Sca-1 or side-population cells ‒ see below) (Laugwitz et al. [@CR40]).

c-kit + cardiac stem cells {#Sec10}
--------------------------

c-kit is a tyrosine kinase surface receptor originally shown to enrich for HSCs. It has now been used to identify stem cell populations in other organs including the heart. Building on their previous study involving sex-mismatched cardiac transplants in humans (Quaini et al. [@CR67]), the same laboratory proposing the presence of endogenous CSCs was able to identify c-kit + CSCs in the hearts of dogs (Linke et al. [@CR46]), mice (Urbanek et al. [@CR89]) and humans (Bearzi et al. [@CR7]). In rats, they found that c-kit + CSCs formed new vasculature and immature myocytes when injected into an infarcted heart (Beltrami et al. [@CR8]), subsequently improving cardiac function. The c-kit + CSCs formed clusters in the interstitia between myocytes and demonstrated signs of early cardiac myogenic differentiation evidenced by expression of the transcription factors *Gata-4, Nkx2-5 and Mef2c*. Furthermore, after in vitro expansion, these cells showed typical characteristics of stem cells, including long term self-renewal, clonogenicity and multipotency.

It is important to note that controversy surrounds the myogenic potential of c-kit + CSCs. In a study by Zaruba et al., the cardiomyogenic ability of c-kit + CSCs was high in neonatal mice but decreased significantly with age and was negligible by adulthood (Zaruba et al. [@CR102]). These findings are supported by other studies, including that by Fazel et al., which also reported that c-kit + CSCs were actually of extra-cardiac origin (Fazel et al. [@CR26]). Before inducing MI in mice, Fazel et al. found that c-kit + cardiac cells were rare (a finding also shared by others (Chong et al. [@CR15]; Beltrami et al. [@CR8])) and 1 month after MI, none of the c-kit + cells were cardiomyocytes. They also found that approximately 74% of c-kit + cardiac cells after MI were in fact BM-derived. Contrasting these reports, a recent transcriptional profiling study by Dey et al. reported a clear difference in the molecular signatures of c-kit + CSCs and c-kit + HSCs (Dey et al. [@CR23]), suggesting different origins and cell fates of BM and cardiac c-kit + cells. Very recently, Berlo et al. used multiple rigorous fate mapping approaches in genetically modified mice to prove that negligible cardiomyocyte contribution occurs from endogenous cardiac c-kit + populations after normal ageing or cardiac injury (van Berlo et al. [@CR91]).

Despite the debate about c-kit + CSCs in preclinical models, the Stem Cell Infusion in Patients with Ischemic Cardiomyopathy (SCIPIO) phase 1 clinical trial proceeded unabated and is currently ongoing (Bolli et al. [@CR9]; Chugh et al. [@CR18]) (Table [2](#Tab2){ref-type="table"}). In this trial, autologous c-kit + CSCs were isolated and expanded ex vivo from patients undergoing coronary artery bypass surgery after MI. Participants were then randomized to receive either intracoronary infusion of these c-kit + CSCs or conventional therapy. Preliminary results of this study showed that isolation and expansion of c-kit + CSCs in this manner was feasible and that subsequent intracoronary delivery did not compromise patient safety (Chugh et al. [@CR18]). Furthermore, a significant improvement in both global and regional LV function and a reduction in infarct size were observed in the c-kit + CSC group when compared to conventional therapy (Bolli et al. [@CR9]). It is important to note that concerns regarding the integrity of certain data generated during the trial have been raised by the Lancet editors (The Lancet Editors [@CR87]) and that concerns regarding patient randomization have also been raised (Nowbar et al. [@CR61]).Table 2**Recent and ongoing clinical trials involving endogenous cardiac stem cells in patients with ischemic cardiomyopathy**Trial name/InvestigatorStudy identifierComparatorsEndpointPatientsDelivery routeType classification**Cardiosphere-derived Stem Cells** ALLSTARNCT01458405Allogeneic CDCs vs placeboInfarct size274IntracoronarySafety + efficacy, Phase 1/2 CADUCEUS\*NCT00893360CDCs (12.5 or 25 million) vs no interventionSafety31IntracoronarySafety, Phase 1**Cardiac Stem Cells + bFGF** ALCADIA\*NCT00981006CSCs + bFGF infusionSafety6IntramyocardialSafety, Phase 1 Cardiac Stem Cells (undefined) Vakilian et al.NCT01758406CSCs vs placeboMortality + LVEF50IntracoronarySafety + efficacy, Phase 2 SCIPIO\*NCT00474461CSCs infusionSAE40IntracoronarySafety + efficacy, Phase 1All trials use autologous infusions unless otherwise stated. Abbreviations: bFGF-Basic Fibroblast Growth Factor, CDCs-Cardiosphere-derived Cells, CSCs-Cardiac Stem Cells, LVEF-Left Ventricular Ejection Fraction, SAE-Serious Adverse Events.\* Denotes trials with published results (including preliminary results).

Cardiosphere-derived cardiac stem cells {#Sec11}
---------------------------------------

The term "cardiosphere" was first coined by Messina et al. describing a population of undifferentiated cells, isolated from cardiac biopsies and obtained by enzymatic digestion of explanted cardiac tissue (Messina et al. [@CR54]). Cardiospheres (CSs) and cardiosphere-derived cells (CDCs) have since been characterized as a heterogenous cell population, containing a central core of c-kit + cells which are surrounded by other cells including those expressing the stromal cell marker CD105. In early preclinical work, CDCs injected into infarcted murine hearts improved cardiac function via apparent differentiation into both cardiomyocytes and vasculature (Messina et al. [@CR54]). Subsequently, a more clinically applicable approach was devised for the isolation and expansion of human CDCs from endomyocardial biopsy specimens (Smith et al. [@CR80]). The authors of this study reported similar findings regarding the cardiac regenerative potential of CDCs after engrafting the cells into infarcted hearts of immunocompromised mice. Techniques later used for the isolation and administration of human CDCs post-MI in clinical trials (see below) were refined using a porcine model of myocardial ischemia/reperfusion (Johnston et al. [@CR35]).

In contrast to the findings above, Andersen et al. used novel culture methods to contest the cardiomyogenic differentiation potential of human CSs (Andersen et al. [@CR3]). They claimed that contamination with myocardial tissue fragments is likely to be responsible for the ability of CSs (isolated from neonatal rats) to spontaneously contract. However, further studies (Davis et al. [@CR21], [@CR22]) have refuted these results, thereby re-establishing CDCs as a promising cardiac cell therapy candidate.

A recent study by Li et al. compared the functional benefits of CDCs to those of enriched c-kit + CSCs, BM-MNCs, BM-MSCs, and AD-MSCs (Li et al. [@CR45]). They found that CDCs had superior potency and myocardial repair efficacy in murine models compared to the other stem cell populations. This suggests that cell interactions amongst the heterogenous CDC cell mix may be advantageous. The model of allogeneic rather than autologous CDC delivery in cardiac cell therapy has also been validated (Malliaras et al. [@CR48]). This further expands their prospective therapeutic potential by enabling an "off the shelf" product.

In addition to c-kit + CSCs, CDCs are the only other CSC to have published results from clinical trials. CADUCEUS (Cardiosphere-Derived Autologous Stem Cells to Reverse ventricular dysfunction) was a prospective, randomized phase 1 trial assessing the safety of autologous intracoronary CDC delivery in patients post-MI (Makkar et al. [@CR47]). Investigators of this study utilized percutaneous techniques to obtain endomyocardial biopsies from which CDCs were isolated and expanded ex vivo. In a later procedure, 2--4 weeks after MI, the expanded CDCs were delivered by intracoronary injection into the infarct-related arteries. Results from the CADUCEUS study show that CDC therapy appears to be safe. Magnetic resonance imaging revealed that at 3 months, CDC treatment reduced scar mass, increased viable heart mass as well as increased regional systolic wall thickening when compared to controls (Makkar et al. [@CR47]). Notably a statistically significant improvement in overall LV function was not reported. Nevertheless, these results have encouraged further investigation of allogeneic CDC therapy in the larger ALLSTAR clinical trial (NCT01458405) (Table [2](#Tab2){ref-type="table"}).

Side-population cardiac progenitors {#Sec12}
-----------------------------------

The cardiac side-population (SP) represents a subpopulation of cardiac progenitors possessing the unique ability to efflux a DNA binding dye (namely Hoechst 33342) conferred by an ATP-binding cassette transporter (Unno et al. [@CR88]). In humans, these protein transporters are encoded by the *ABCG2* gene, which can be used as a determinant of the SP cell phenotype (Martin et al. [@CR49]). SP cells comprise 4%, 2% and 1.2% of cells in the fetal, neonatal, and adult rat heart, respectively (Leri et al. [@CR42]). Initial reports by Hierlihy et al. indicate that cardiac SP cells (C-SPs) display stem cell activity, lack markers of differentiated cell lineages, and possess significant cardiomyogenic potential in vitro (Hierlihy et al. [@CR33]). Confirming the latter findings, Martin et al. found that C-SPs expressed α-ACTININ (myocyte protein) when co-cultured with cardiac main population cells (Martin et al. [@CR49]), indicating possible cardiomyocyte differentiation potential.

Similar to other CSC populations, the origin of C-SPs has been questioned. To address a possible BM origin for C-SPs, Mouquet et al. transplanted fluorescently labeled BM into wild-type adult mice (Mouquet et al. [@CR58]) and investigated the effect of MI on these cells. Injured hearts demonstrated an acute depletion of C-SPs following MI, which was replenished (by up to 25%) by fluorescently labeled BM-derived stem cells within 7 days. These cells then proceeded to adopt a C-SP phenotype, suggesting that a significant portion of the C-SP population is in fact BM-derived, rather than solely of cardiac origin. Combining cell surface marker studies with lineage tracing experiments will enable more accurate tracking of C-SP origins and cell fates in vivo, allowing for better characterization of their cardiac regenerative abilities.

Sca-1+ cardiac stem cells {#Sec13}
-------------------------

Stem cell antigen-1 (Sca-1) is widely used to enrich HSCs in mice (Holmes and Stanford [@CR34]). Humans lack the murine Sca-1 gene and it is currently unknown whether there is a true human orthologue. Sca-1+ CSCs were first characterized in the adult murine myocardium by Oh et al. as cardiac stem/progenitor cells lacking hematopoietic lineage markers (Oh et al. [@CR62]). Prior to stimulation with 5-AZA, freshly isolated Sca-1+ CSCs expressed the cardiogenic transcription factors *Gata-4, Mef2c and Tef-1*. Upon stimulation, a small percentage of these cells began to express cardiac structural genes (sarcomeric α-actin, *Tnni3, Nkx2-5, β-Mhc and α-Mhc*) and consequently acquired a phenotype resembling that of cardiomyocytes. The authors reported that intravenously delivered Sca-1+ CSCs home to sites of tissue injury and form new cardiomyocytes in mice post-MI, presenting a more clinically applicable view of their regenerative potential.

Matsuura et al. subsequently demonstrated Sca-1+ CSC multipotency by showing differentiation into osteocytes and adipocytes (Matsuura et al. [@CR51]). Furthermore, they demonstrated that refined in vitro procedures using oxytocin instead of 5-AZA to stimulate Sca-1+ CSC differentiation resulted in the generation of spontaneously beating cardiomyocytes. This added weight to the evidence supporting the in vitro cardiac differentiation capacity of Sca-1+ CSCs. Further experimentation by Wang et al. revealed that it is in fact the Sca-1+/CD31- sub-population that possesses cardiomyogenic potential (Wang et al. [@CR96]).

Notably, murine transgenic technology has provided valuable insight into the molecular role of Sca-1+ CSCs. Tateishi et al. demonstrated that knockdown of Sca-1 transcripts in CSCs led to retarded ex vivo expansion and cell apoptosis (through Akt inactivation) (Tateishi et al. [@CR85]). Their results also show that cardiomyocytes require Sca-1 to upregulate secretion of paracrine effectors which induce angiogenesis and limit cardiac apoptosis. This implies that therapeutically, Sca-1 may promote CSC survival following engraftment into injured tissue and will in turn influence revascularization and cardiac repair.

Epicardium derived cells {#Sec14}
------------------------

The epicardium is the outer layer of heart and inner layer of the pericardium, consisting predominantly of mesothelial cells and dense connective tissue. Epicardium-derived cells (EPDCs) have long been known to play a fundamental role in the developing embryonic heart. Although these cells were thought to be quiescent in healthy adult hearts, recent evidence suggests that injury-associated signals after MI induce reactivation of EPDCs, promoting heart regeneration and injury reduction (Zhou et al. [@CR104]). Another study has described this process as epithelial to mesenchymal transformation involving the migration of multipotent EPDCs from the epicardium to the subepicardial matrix, subsequently forming coronary vasculature and cells of the cardiac interstitium (van Tuyn et al. [@CR92]). Paracrine mediators secreted by EPDCs have been shown to underlie their regenerative potential (Zhou et al. [@CR104]); however, their direct contribution to the cardiomyocyte and endothelial cell lineages remains controversial (Wessels and Perez-Pomares [@CR97]).

Smart et al. recently demonstrated that preconditioning of adult murine hearts with thymosin β4 (crucial for neovascularization of the neonatal heart), prior to infarction, significantly activated the quiescent epicardium (Smart et al. [@CR79]). Activation led to EPDC mobilization and neovascularization of the heart following MI, suggesting that the adult mammalian epicardium harbors significant regenerative potential. These recent studies highlight the therapeutic potential of multipotent EPDCs found in the postnatal mammalian heart.

Sca-1+/PDGFRα + cardiac stem cells {#Sec15}
----------------------------------

Amongst the various Sca-1+ subpopulations, a study by Chong et al. identified a stem cell population that co-expresses Sca-1 and platelet derived growth factor receptor α (PDGFRα) (Chong et al. [@CR15]). By comprehensive lineage tracing experiments in genetic mouse models, this CSC population was found to originate from the embryonic epicardium (Chong et al. [@CR15]) and exhibited the cardinal features of stem cells (self-renewal, clonogenicity and multipotency). Similar to BM-MSCs, Sca-1+/PDGFRα + CSCs can form clonal colonies and were therefore called cardiac colony-forming unit fibrolasts (cCFU-Fs). Recently, the same CSC population described in these murine studies has been identified in human hearts (Chong et al. [@CR16]). It is likely that cCFU-Fs contribute to the regenerative features observed in EPDCs, but further verification is required to characterize the extent and mechanism of their contribution to cardiac regeneration of injured hearts.

Delivery {#Sec16}
========

No agreement has been reached regarding the optimum method of delivery of transplanted cells; intramyocardial (IM), intravenous (IV) and intracoronary (IC) delivery methods are all used interchangeably. The most clinically practiced form of cell delivery is the IC approach which provides a direct route of cell delivery via coronary arteries to myocardial sites of interest (Sheng et al. [@CR78]). This procedure is normally carried out simultaneously during percutaneous coronary intervention post-MI. Whilst being safe and efficient, 1 major limitation of this procedure is that cells are not able to reach areas of myocardium that are poorly perfused.

IV injections are only used selectively in patients following MI, as they rely on physiological homing signals from injured heart tissue, a state not present in chronic heart failure. Although widely inefficient, IV infusions are simple and minimally invasive. In contrast, transepicardial IM delivery is significantly invasive but provides the most direct and precise delivery method. Transendocardial IM delivery via percutaneous delivery catheters has been developed as possibly the most efficient yet least invasive delivery method. The AlsterMACS (Intracoronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells) trial (NCT01337011) compares 2 of the above delivery techniques, IC and IM, in order to establish a universal mechanism for the administration of stem cells to patients with ischemic heart disease (Table [1](#Tab1){ref-type="table"}). Another trial run by Vrtovec et al. states through preliminary results that transendocardial IM cell transplantation is associated with higher retention rates and greater improvement in ventricular function compared with IC administration (Vrtovec et al. [@CR94]) (NCT01350310).

In addition to conventional delivery methods, various tissue engineering techniques provide novel approaches to improve sustainability and accuracy of cell culture transplantation, augmenting the effects of transplanted cells.

Summary and prospects {#Sec17}
=====================

The long held view of the human adult heart as a quiescent organ incapable of regeneration has only recently been successfully challenged. It is now clear that the heart possesses a small but significant ability to regenerate after insults such as MI. Stem Cell therapy can enhance this ability and may ultimately provide a viable clinical therapy to treat post-MI cardiac dysfunction. However, considerable work remains. Fore mostly, the best candidate cell type needs to be elucidated. This will likely become clear with time. In addition, the mechanisms underpinning favorable cardiac effects of most, if not all of the stem cells reviewed, are incompletely understood. Although not a prerequisite for clinical therapy, mechanistic understanding will aid further refinement of cardiac cell therapy and will speed effective clinical translation. We strongly believe that cardiac regeneration, either by delivery of extra-cardiac stem cells or by enhancing endogenous mechanisms, will change the future of MI treatment.
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